Display options
Cite
Begg L, Brodsky R, Friedland B, et al. Estimating the market size for a dual prevention pill: adding contraception to pre-exposure prophylaxis (PrEP) to increase uptake. BMJ Sex Reprod Health. 2020;47(3):166-172doi: 10.1136/bmjsrh-2020-200662.
Begg, L., Brodsky, R., Friedland, B., Mathur, S., Sailer, J., & Creasy, G. (2021). Estimating the market size for a dual prevention pill: adding contraception to pre-exposure prophylaxis (PrEP) to increase uptake. BMJ sexual & reproductive health, 47(3), 166-172. https://doi.org/10.1136/bmjsrh-2020-200662
Begg, Lorna, et al. "Estimating the market size for a dual prevention pill: adding contraception to pre-exposure prophylaxis (PrEP) to increase uptake." BMJ sexual & reproductive health vol. 47,3 (2021): 166-172. doi: https://doi.org/10.1136/bmjsrh-2020-200662
Begg L, Brodsky R, Friedland B, Mathur S, Sailer J, Creasy G. Estimating the market size for a dual prevention pill: adding contraception to pre-exposure prophylaxis (PrEP) to increase uptake. BMJ Sex Reprod Health. 2021 Jul;47(3):166-172. doi: 10.1136/bmjsrh-2020-200662. Epub 2020 Jul 31. PMID: 32737137; PMCID: PMC8292580.
Copy Download .nbib Format: NLM
Share it on

BMJ Sex Reprod Health. 2021 Jul;47(3):166-172. doi: 10.1136/bmjsrh-2020-200662. Epub 2020 Jul 31.

Estimating the market size for a dual prevention pill: adding contraception to pre-exposure prophylaxis (PrEP) to increase uptake.

BMJ sexual & reproductive health

Lorna Begg, Rebecca Brodsky, Barbara Friedland, Sanyukta Mathur, Jim Sailer, George Creasy

Affiliations

  1. Center for Biomedical Research, Population Council, New York, New York, USA [email protected].
  2. Center for Biomedical Research, Population Council, New York, New York, USA.
  3. HIV and AIDS, Population Council, New York, New York, USA.
  4. HIV and AIDS, Population Council, Washington, District of Columbia, USA.

PMID: 32737137 PMCID: PMC8292580 DOI: 10.1136/bmjsrh-2020-200662

Abstract

INTRODUCTION: Uptake of oral pre-exposure prophylaxis (PrEP) remains low. The objective of this analysis was to estimate the potential market size in priority sub-Saharan African countries for a 28-day dual prevention pill (DPP) regimen containing the active pharmaceutical ingredients in oral PrEP and oral contraceptive pills (OCPs) for the prevention of HIV and unintended pregnancy.

METHODS: We selected 15 countries in sub-Saharan Africa for analysis. Population estimates were based on United Nations Population Division data from 2017. Low, medium and high rates (range 0.25% to 25%) of estimated conversion from current contraceptive method to the DPP were applied by country based on HIV prevalence (≥10% vs <10%), current contraceptive method (OCP, condom or unmet need for contraception) and age group (15-24 or 25-49 years).

RESULTS: In these 15 countries, between 250 000 and 1.25 million women could switch from their current contraceptive method to the DPP. Given that current PrEP use in the 15 countries combined is estimated to be 113 250 (women and men), the most conservative market size estimate would more than double the number of women currently using PrEP.

CONCLUSIONS: By leveraging the existing market for OCPs and assuming modest conversion from condom users and women with an unmet need for contraception, the DPP could lead to a 2- to 10-fold increase in PrEP usage in these 15 sub-Saharan African countries, expanding the broader public health benefit of this proven HIV prevention strategy.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Keywords: HIV; contraceptive agents, female; contraceptives, oral; reproductive health; sexually transmitted diseases

Conflict of interest statement

Competing interests: None declared.

References

  1. Fertil Steril. 2016 Nov;106(6):1295-1302 - PubMed
  2. J Int AIDS Soc. 2018 Mar;21(3):e25094 - PubMed
  3. J Adolesc Health. 2018 Mar;62(3):273-280 - PubMed
  4. BMC Womens Health. 2018 Feb 05;18(1):35 - PubMed
  5. PLoS One. 2020 Jan 13;15(1):e0227632 - PubMed
  6. BJOG. 2014 Oct;121 Suppl 5:27-34 - PubMed
  7. N Engl J Med. 2015 Feb 5;372(6):509-18 - PubMed
  8. Int J Gynaecol Obstet. 2015 Aug;130 Suppl 3:E21-4 - PubMed
  9. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):46-53 - PubMed
  10. N Engl J Med. 2012 Aug 2;367(5):411-22 - PubMed
  11. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD010243 - PubMed
  12. J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):452-61 - PubMed
  13. AIDS Behav. 2018 Jan;22(1):133-145 - PubMed
  14. BMC Womens Health. 2017 Apr 04;17(1):25 - PubMed
  15. Retrovirology. 2018 Apr 2;15(1):29 - PubMed
  16. Lancet HIV. 2016 Sep;3(9):e406-e408 - PubMed
  17. BJOG. 2014 Oct;121 Suppl 5:70-8 - PubMed
  18. Contraception. 2018 Mar;97(3):277-284 - PubMed
  19. BJOG. 2014 Oct;121 Suppl 5:45-52 - PubMed

MeSH terms

Publication Types